74 related articles for article (PubMed ID: 9472561)
1. Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging.
Scardigli R; Bossi G; Blandino G; Crescenzi M; Soddu S; Sacchi A
Gene Ther; 1997 Dec; 4(12):1371-8. PubMed ID: 9472561
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells.
Hirai M; LaFace D; Robinson S; Kelsey L; Johnson R; Wen SF; Warkentin P; Mills K; Vaillancourt M; Chavez J; Leutzinger C; Sumegi J; Neugebauer S; Lehman J; Talmadge C; Maneval D; Talmadge J
Cancer Gene Ther; 2001 Dec; 8(12):936-47. PubMed ID: 11781656
[TBL] [Abstract][Full Text] [Related]
3. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells.
Martinelli R; Blandino G; Scardigli R; Crescenzi M; Lombardi D; Sacchi A; Soddu S
Oncogene; 1997 Jul; 15(5):607-11. PubMed ID: 9247315
[TBL] [Abstract][Full Text] [Related]
4. Development of a gene therapy based bone marrow purging system for leukemias.
Huang W; Tan W; Zhong Q; Schwarzenberger P
Cancer Gene Ther; 2005 Nov; 12(11):873-83. PubMed ID: 15891774
[TBL] [Abstract][Full Text] [Related]
5. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
6. Development of a murine orthotopic model of leukemia: evaluation of TP53 gene therapy efficacy.
Bossi G; Scardigli R; Musiani P; Martinelli R; Gentileschi MP; Soddu S; Sacchi A
Cancer Gene Ther; 2000 Jan; 7(1):135-43. PubMed ID: 10678366
[TBL] [Abstract][Full Text] [Related]
7. Cryopreservation of human bone marrow after purging T-cells or tumor cells.
Zhang ZX; Xu YJ; Chen Y; Li Y; Shen BF; Bai Y
Cryobiology; 1994 Oct; 31(5):478-82. PubMed ID: 7988157
[TBL] [Abstract][Full Text] [Related]
8. Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model.
Garcia-Castro J; Rio P; Lillo R; Garcia-Sanchez F; Segovia JC; Bueren JA
Gene Ther; 2003 Aug; 10(16):1328-35. PubMed ID: 12883529
[TBL] [Abstract][Full Text] [Related]
9. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma.
Holmgren L; Jackson G; Arbiser J
Oncogene; 1998 Aug; 17(7):819-24. PubMed ID: 9779998
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis.
George SJ; Angelini GD; Capogrossi MC; Baker AH
Gene Ther; 2001 May; 8(9):668-76. PubMed ID: 11406761
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro.
Saeki T; Mhashilkar A; Chada S; Branch C; Roth JA; Ramesh R
Gene Ther; 2000 Dec; 7(23):2051-7. PubMed ID: 11175318
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ.
Wang TJ; Huang MS; Hong CY; Tse V; Silverberg GD; Hsiao M
Biochem Biophys Res Commun; 2001 Sep; 287(1):173-80. PubMed ID: 11549271
[TBL] [Abstract][Full Text] [Related]
13. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
14. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo.
Riccioni T; Cirielli C; Wang X; Passaniti A; Capogrossi MC
Gene Ther; 1998 Jun; 5(6):747-54. PubMed ID: 9747454
[TBL] [Abstract][Full Text] [Related]
16. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
18. Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells.
Cascalló M; Mercadé E; Capellà G; Lluís F; Fillat C; Gómez-Foix AM; Mazo A
Cancer Gene Ther; 1999; 6(5):428-36. PubMed ID: 10505853
[TBL] [Abstract][Full Text] [Related]
19. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF
Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
